# Benjamin Rovinski

> Benjamin Rovinski is a Series B investor at Lumira Ventures backing Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures)
- Location: Toronto, Canada
- Total investments: 10
- Last investment: Jun 2026
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/benjamin-rovinski-5063a11
- Website: https://www.lumiraventures.com/team-member/beni-rovinski-phd

Benjamin Rovinski is a Series B investor at Lumira Ventures in Toronto focused on Biotechnology and Therapeutics. With over 30 years of investment, operational, managerial and research experience in the healthcare industry, Beni has helped build life sciences companies at all stages of development. Known both as a senior scientist and as an achievement-oriented executive, with demonstrated success in strategic planning, drug development, and operationalmanagement of global multifunctional teams, Beni has established a sound reputation built on his clarity of objectives, leadership, judgement and integrity.Beni’s investment focus is primarily on North American mid- to late-stage private and public companies involved in drug discovery and development, biological and small molecule therapeutics, drug delivery, specialty pharmaceuticals, genomics, proteomics and diagnostic devices.With a proven track record of delivering results both as a senior scientist and a business executive, Beni has held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur (formerly Aventis Pasteur) where he was a senior scientist and director of molecular virology, with a particular focus in the areas of virology, vaccine development, recombinant protein production, and functional genomics. While at Aventis, Beni led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines (e.g., colorectal, prostate and cervical cancers), bringing several of them through to clinical stage.Beni is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 32 issued patents.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 70% |
| Therapeutics | 5 | 50% |
| Health Care | 2 | 20% |
| Pharmaceutical | 2 | 20% |
| Medical | 1 | 10% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 50% |
| Series A | 3 | 30% |
| Seed | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 60% |
| Canada | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M | Series B | Jun 18, 2026 |  |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $105M | Series A | Jan 30, 2024 |  |
| OncoMyx Therapeutics | OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by humanleukocytes where it can then infect tumor cells.The company was founded in 2018 and is headquartered in Phoenix, Arizona. | $50M | Series B | Dec 09, 2021 |  |
| Viron | OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit ofcancer patients. | $50M | Series B | Dec 08, 2021 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $75M | Series B | Nov 03, 2021 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $96M | Series B | Apr 12, 2021 |  |
| Iterion Therapeutics | Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivintdemonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.It was founded in 2010 and is headquartered in Houston, Texas. | $17M | Series B | Feb 16, 2021 |  |
| Bright Angel Therapeutics | Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance,enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens. |  | Seed | Dec 03, 2019 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $25M | Series A | Nov 27, 2018 |  |
| Vascular Pharmaceuticals | Vascular Pharmaceuticals is a drug discovery company developing monoclonal antibody treatments for diabetic nephropathy. The company specializes in the fields of biotechnology, medicine, and healthcare. It was founded in 2005 and headquartered in Tarboro, North Carolina. | $9M | Series A | Mar 20, 2015 |  |

10 of 10 investments shown.

## Co-investors
- [Soleus Capital](https://shizune.co/investors/profile/soleus-capital) — VC Fund, 4 deals together
- [CAM Capital](https://shizune.co/investors/profile/camcapital) — VC Fund, 3 deals together
- [Delos Capital](https://shizune.co/investors/profile/delos-capital-%E5%BA%B7%E7%A6%A7%E5%85%A8%E7%90%83%E6%8A%95%E8%B3%87%E5%9F%BA%E9%87%91) — VC Fund, 3 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 3 deals together
- [Sixty Degree Capital](https://shizune.co/investors/profile/quantum-vista-capital) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together

## About Lumira Ventures

VC Fund · Toronto, Canada

With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meetingsignificant unmet needs and creating transformation impact in communities worldwide.Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.

5 contacts available at Lumira Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Baye Galligan, M.A., HBA | Associate | https://shizune.co/investors/profile/baye-galligan |
| Benjamin Rovinski | Managing Director | https://shizune.co/investors/profile/beni-rovinski |
| Brian J. Underdown, Ph.D. | Venture Partner | https://shizune.co/investors/profile/brian-j-underdown |
| Daniel Hetu | Managing Director | https://shizune.co/investors/profile/daniel-hetu |
| Lu Han | Director, Business Development Asia Pacific | https://shizune.co/investors/profile/lu-han |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Benjamin Rovinski invest in?

Benjamin Rovinski invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Benjamin Rovinski last invest?

The most recent investment recorded for Benjamin Rovinski closed in Jun 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co